Objectives: The objectives of this study were to characterize contemporary MRSA isolates and understand the prevalence and impact of sequence variability in PBP2a on ceftaroline susceptibility.
Introduction
MRSA is a causative pathogen for a diverse range of diseases including skin infections, bacteraemia, wound infections and abscesses as well as pneumonia. MRSA is a leading source of hospital-acquired infections and since the first molecular description of the highly virulent community-associated MRSA clone just over a decade ago, 1 the prevalence of community-associated MRSA has drastically increased and this clone is becoming established in hospitals. Further, given the significant morbidity and mortality caused by MRSA infections, new treatment options are required as resistance continues to develop, as evidenced by the recent finding of vancomycin resistance genes carried on a transmissible plasmid in a community-associated MRSA clone. 2 Methicillin resistance in Staphylococcus aureus is mediated by the horizontal acquisition of the staphylococcal cassette chromosome (SCC) that carries the mecA allele, which encodes an alternative PBP (MecA or PBP2a), although several other genetic factors have been linked to the full expression of b-lactam resistance.
3 -5 b-Lactam drugs, including methicillin, bind to 'native' PBPs and inhibit the transpeptidation reaction required during peptidoglycan synthesis. However, most b-lactam molecules have a poor binding affinity for PBP2a, which, once acquired, functionally complements the transpeptidation reaction and allows cell wall biogenesis to proceed in the presence of these b-lactams. Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin that has high affinity for PBP2a while maintaining high affinity for other essential S. aureus PBPs. 6 This results in the anti-MRSA activity of ceftaroline. 7, 8 Epidemiological studies on MRSA have shown that the SCCmec element has been acquired independently into multiple different MSSA lineages and these organisms have subsequently disseminated globally. 9, 10 Such epidemiological studies have relied on a range of typing methods to show genetic relatedness between isolates, such as PFGE, S. aureus protein A (spa) typing, SCCmec typing and MLST, to track both the evolution and spread of S. aureus. Indeed, several of the most widely spread clones of S. aureus have been found with multiple different SCCmec cassettes, supporting the concept that the genetic basis for b-lactam resistance has been acquired multiple times into a single genetic lineage. 9, 10 The rapid advancement of next-generation sequencing and the associated bioinformatics platforms, with their extremely high discriminatory power, have transformed microbiology. These techniques can be used to understand the molecular evolution of a bacterial species as well as to rapidly understand the transmission dynamics of a pathogen and are likely to play an important role in the control of infectious disease outbreaks in the future. 11 -13 The microbiological activity of ceftaroline and comparator agents is being monitored and tracked through an ongoing global surveillance programme known as AWARE (Assessing Worldwide Antimicrobial Resistance Evaluation). During 2010, four isolates (one from Spain and three from Thailand) exhibited ceftaroline MIC values of .2 mg/L and were genetically characterized. 8 These isolates were each found to carry two substitutions in PBP2a, both converting a glutamic acid into a lysine. One substitution was located in the ceftaroline-binding pocket in the penicillin-binding domain (PBD; E447K) and the associated charge reversal was predicted to weaken the binding affinity of ceftaroline, whereas the other substitution was located in the non-penicillin-binding domain (nPBD; E239K). This is a region of PBP2a that has been proposed to be functionally important during cell wall biosynthesis, either by interaction with other PBPs 8 or other ligands, such as cell wall fragments, that may regulate the transpeptidase pocket via allostery.
14 The E239K nPBD variation was also identified in MRSA isolates collected from the same hospitals in Spain and Thailand that had ceftaroline MIC values of 2 mg/L, which are considered non-susceptible and reported as intermediate by the current CLSI interpretive criteria 15 and are considered resistant using the current EUCAST clinical breakpoints. 16 Importantly, WGS confirmed that these isolates were epidemiologically related and distinct from other MRSA isolates of the same MLST-SCCmec type. 8 The objective of this study was to examine a large set of internationally distributed MRSA isolates collected during 2012 that are inhibited by ≥2 mg/L ceftaroline to evaluate the epidemiological relatedness of these isolates and better understand the interplay between any sequence variation of the nPBD and PBD of PBP2a and any impact on ceftaroline susceptibility. 
Materials and methods

Collection of bacterial isolates
Antimicrobial susceptibility testing
The MIC for each isolate was determined using the broth microdilution method following CLSI guidelines. 15 S. aureus ATCC 29213 was used as the quality control isolate. Ceftaroline was obtained from Cerexa (Oakland, CA, USA).
WGS and analysis
Genomic DNA purified on the Maxwell 16 platform (Promega, Madison, WI, USA) and quantified using the Qubit fluorometer (Invitrogen Life Technologies, Grand Island, NY, USA) was used as input material for library construction. DNA libraries were prepared using the Nextera library construction protocol (Illumina, San Diego, CA, USA) following the manufacturer's instructions and sequenced on a MiSeq Sequencer (Illumina, San Diego, CA, USA). For each isolate, 2.5 million 150 bp paired-end sequence reads were de novo assembled and analysed using the CLCBio suite of software tools (Cambridge, MA, USA). The SCCmec types of the MRSA isolates were determined by comparison with reference sequences. The MLST profiles of the isolates were determined by comparison of the seven allele sequences with the curated public database available at http://saureus. mlst.net.
Molecular modelling
Various structures of WT PBP2a in the unbound form (PDB:1MWT) or bound with ceftaroline (PBD:3ZG0 and PDB:3ZFZ) or a peptidoglycan analogue (PDB:3ZG5), as well as PBP2a proteins carrying nPBD changes (PDB:4BL2, PDB:4BL3 and PDB:4CPK), available in the public PDB database, were used for the structural analyses. The structures were visualized and the mutations identified in this study were mapped using the graphics program PyMOL (Schrö dinger; www.pymol.org).
Results
Worldwide surveillance data on MRSA isolates
A total of 4324 MRSA isolates were collected from a total of 32 different countries and tested during the AWARE 2012 global surveillance programme ( Table 1 ). The overall MRSA MIC 90 value of ceftaroline was 2 mg/L. However, the MIC 90 value varied between geographical regions and was 1 mg/L in Europe and 2 mg/L in Latin America, the Asia-Pacific region and the Middle East-Africa (Table 1 ). These MIC 90 values are entirely consistent with other large surveillance studies in past years from the different geographical regions, 8,17 -21 suggesting that no significant change in the susceptibility of global MRSA isolates to ceftaroline has occurred. The MIC 90 value of ceftaroline over several large surveillance studies has been shown to be 1 mg/L in the USA. 8, 22, 23 In 2012, there were 38 MRSA isolates collected that were inhibited by .2 mg/L of ceftaroline and 603 MRSA isolates that had an MIC of 2 mg/L during the initial susceptibility testing at the central laboratory. Of the 38 isolates that had a ceftaroline value of .2 mg/L, 30 originated from the Asia-Pacific region, with 28 being isolated in Thailand (two different collection sites) and single isolates from both Japan and South Korea. The remaining eight isolates were from Europe, with six originating from Italy (three different collection sites) and two isolates from a single hospital in Spain (Table 1) .
Of the 603 MRSA isolates with a ceftaroline MIC of 2 mg/L, approximately a third each were from the Asia-Pacific region Number of isolates brought in for genetic characterization, which is a subset of the number of isolates tested from that particular country. Ten of these isolates consistently had a ceftaroline MIC of 8 mg/L upon multiple retests.
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Colombia was also 2 mg/L; it was a dilution lower in Mexico and Venezuela (Table 1) . There was no apparent bias in the type of infections amongst isolates with a ceftaroline MIC value of ≥2 mg/L, with approximately half of the isolates being obtained from respiratory samples (sputum, tracheal aspirates etc.) and the remainder from wounds, abscesses and urinary tract infections. Additionally, no association was observed between the ceftaroline MIC value and the length of hospitalization.
Characterization of representative MRSA surveillance isolates
Representative MRSA strains from each country that had isolates with an initial ceftaroline MIC value of 2 mg/L (n¼ 98) or 4 mg/L (n¼ 21) were obtained from the central laboratory for repeat susceptibility testing and WGS (Table 1 ). In addition, a total of 65 representative MRSA isolates that tested with an initial ceftaroline MIC value of ≤1 mg/L were obtained from 22 different countries (Table 1) . After repeat susceptibility testing, there were eight isolates (4.3%) that were classified differently according to the current CLSI and EUCAST susceptible breakpoints of ≤1 mg/L; three isolates had ceftaroline MIC values go from 2 to 1 mg/L and five isolates had values go from 1 to 2 mg/L. Of note, however, all but one of the isolates from Thailand that exhibited an original ceftaroline MIC value of 4 mg/L retested at 8 mg/L, similar to the observation seen previously. 8 After the repeat susceptibility testing, the final analysis set studied consisted of 121 and 63 MRSA isolates with ceftaroline MIC values of ≥2 and ≤1 mg/L, respectively. WGS on all isolates was used to determine the MLST type and SCCmec type and to examine any variations in the PBP2a protein in these isolates. During the subsequent analyses, a 'WT PBP2a' sequence was defined as that identified in S. aureus N315, JKD6008 and USA300 as representatives of ST5, ST239 and ST8, respectively (GenBank identifiers BAB41256, ADL64125 and ADV68980), for two reasons. First, they represent the most prevalent sequence among the MRSA reference strains that have been sequenced 8 and, second, they represent the most prevalent PBP2a sequence in the public domain database (GenBank), representing .90% of the .3300 sequences analysed.
Genotyping of MRSA isolates with ceftaroline MIC values of ≥2 mg/L
Twenty-three of the 121 isolates (19.0%) in this group had a WT PBP2a sequence ( Table 2 ). All of these isolates exhibited a ceftaroline MIC of 2 mg/L, belonged to nine distinct MLST types and originated from 13 different countries. In contrast, the remaining 98 isolates carried different PBP2a variations, but were concentrated in far fewer MLST types, with 89.8% (n¼ 88 isolates) being represented in three lineages (ST5 ¼ 38, ST228 ¼ 31 and ST239 ¼ 19) ( Table 2 ). Almost two-thirds of the isolates with PBP2a variations (n¼ 64) carried the SCCmec type I cassette ( Table 2 ). The majority of the variation in the PBP2a sequences was located in the nPBD (discussed in more detail below). Indeed, the only substitution identified in the transpeptidase pocket in the PBD was found in 12 ST228-MRSA-I isolates from Thailand that all carried the E239K/E447K mecA allele that had previously been isolated from Thailand in 2010. 8 Genotyping of MRSA isolates with ceftaroline MIC values of ≤1 mg/L As there was an apparent enrichment of PBP2a variations and MLST types in the isolates exhibiting a ceftaroline MIC of ≥2 mg/L, the analysis of 63 MRSA isolates with ceftaroline MIC values of ≤1 mg/L was included to confirm this trend. Four susceptible MRSA isolates were excluded from the analysis, all of which lacked a mecA gene, but contained other remnants of an SCCmec cassette. Of the remaining 59 isolates, 33 (55.9%) carried a WT PBP2a protein (Table 2) . Fourteen isolates (23.7%) carried a single G246E substitution similar to the ceftaroline-susceptible MRSA reference strain COL 8 and 5 (8.5%) carried an S225R substitution. Analyses of the PBP2a sequences in the public domain demonstrate that one of these two PBP2a variations is found in .100 MRSA isolates. However, neither of these changes was singularly found in any isolate that exhibited a ceftaroline MIC of ≥2 mg/L. Of the remaining seven isolates, two from Belgium carried a D39N variation, whereas five isolates, all of which were inhibited by 1 mg/L ceftaroline, contained nPBD variations similar to those in isolates with ceftaroline MIC values of ≥2 mg/L. These isolates were from China (E239K), Chile (M122I/E150K/D586Y), Thailand (one with N146K and the other with N146K/N204K/ G246E) and France (E239K/G246E). There was no enrichment of MRSA clonal lineages in these isolates, with 22 different MLST types being represented in the 59 isolates. However, 40 of the isolates (67.8%) carried the SCCmec type IV, typically linked with community-associated MRSA ( Table 2) .
Analysis of PBP2a genotype and ceftaroline susceptibility
The susceptibility and genetic data were combined to understand the relationships between PBP2a sequence variability and ceftaroline susceptibility. From the analysis, it was apparent that the isolates with exclusively nPBD variations have ceftaroline MIC values that range from 0.5 to 4 mg/L (Figure 1) . Importantly, isolates with a WT PBP2a sequence had a ceftaroline MIC distribution that ranged from 0.5 to 2 mg/L. There were 23 among the 102 isolates with a ceftaroline MIC of 2 mg/L that carried a WT PBP2a sequence, whereas the rest all contained nPBD variations. This finding suggests that factors other than the PBP2a sequence can influence ceftaroline susceptibility.
There were a variety of nPBD sequence variations observed in the isolates exhibiting ceftaroline MIC values of ≥2 mg/L, but three variations were significantly more prevalent, E150K, E239K and N146K (Figure 2 ). These three variations have been observed in multiple MLST lineages of MRSA (Table 3) , suggesting separate independent mutational events rather than dissemination. Of these, E239K and N146K are predominantly present as a single change and isolated in multiple countries in Europe and the AsiaPacific region. In contrast, the E150K variation was found almost exclusively in combination with M122I (31 out of 34 observations) and all of the M122I/E150K isolates were isolated from countries in Latin America. Other than these three prevalent variations, there are 11 unique nPBD variations that comprise a smaller fraction (9.1%) of the isolates exhibiting ceftaroline MIC values of ≥2 mg/L (Figure 2 ). There were 10 MRSA isolates that generated a ceftaroline MIC of 8 mg/L upon repeat testing, all of which contained a variation, E447K, in the PBD together with an E239K nPBD Characterization of ceftaroline-non-susceptible S. aureus isolates Characterization of ceftaroline-non-susceptible S. aureus isolates 2493 JAC substitution; these were collected from Thailand and were from the same ST228-MRSA-I lineage observed in the 2010 surveillance isolates. 8 Interestingly, there were two isolates with this PBP2a genotype from Thailand that reproducibly generated ceftaroline MIC values of 4 mg/L, supporting the notion that other genetic factors subtly influence ceftaroline susceptibility.
Location and impact of PBP2a substitutions
Changes in the PBD
The most common substitution observed in the PBD was E447K located in the transpeptidase-binding pocket and that interacts directly with the R2 group of ceftaroline (Figure 3b) . The E447 residue is located adjacent to Y446 that forms an active-site gate with M641. 24 The E447K mutation likely results in a new salt bridge with residues E460 and T582, which would occlude the pocket and prevent optimal binding of the R2 group.
There were two other PBD variations in PBP2a observed in this study, D586Y and I563T. The D586Y substitution was observed in a single isolate in combination with the prevalent nPBD allele M122I/E150K, whereas the I563T variation was observed in combination with the commonly observed N146K variation. Both of these PBD residues are located a significant distance from the transpeptidase pocket (Figure 3a) . Whereas it is unlikely that these PBD variations impact the susceptibility profile to ceftaroline, as the ceftaroline MIC values of these isolates were 1 and 2 mg/L, respectively, isogenic mutants and associated biochemical studies would be required to confirm any impact.
Changes in the nPBD
The PBP2a substitutions that result in a ceftaroline MIC of 2-4 mg/L were primarily located in the nPBD region of the protein. This region, also called the dimerization domain, has been hypothesized to be an important protein interface that interacts with other PBP partners during cell wall biosynthesis. 8 This region has also been shown to crystallize with cell wall fragments and a second ceftaroline molecule and has been implicated in the allosteric control of the transpeptidase-binding pocket.
14 The majority of the substitutions observed in the nPBD, including the prevalent E150K and E239K, are located in a groove in this domain and are in close proximity to each other such that combinations of these changes would influence the charge distribution of the outer surface (Figure 3c ). Also noteworthy is that N146K is in close proximity to the second ceftaroline molecule observed in the crystal structure. 14 Many of the remaining PBP2a changes that are observed less frequently (D139W, N204K, A228V, N236K, T235I and T238I) also map to solvent-exposed regions of this cleft in the protein (Figure 3a and c) . The nPBD variations that are more distant from this area are M122I, K281R and K290Q (Figure 3a ). Of these, the M122I variation always coexists with E150K, whereas isolates that contain the single K281R and K290Q variations exhibit ceftaroline MIC values of 2 and 4 mg/L, respectively. The only variation that was not located on the protein surface was the L357I substitution that lay in the hydrophobic core of the nPBD. While this change may exert subtle effects on the dynamics of PBP2a, biochemical and biophysical studies would be required to determine the impact.
Epidemiological relatedness of MRSA isolates exhibiting ceftaroline MIC values of ≥2 mg/L
Whereas there was no discernible bias of the MLST lineages observed among the ceftaroline-susceptible isolates (MIC ≤1 mg/L), there was a distinct enrichment of MLST lineages amongst isolates that were inhibited by ≥2 mg/L ceftaroline. The largest clonal complex (CC) represented was CC5 with 86 isolates, followed by CC8 with 30 isolates. Besides these two CCs, there were three CC22 isolates (all ST22) and two CC36 isolates (both ST36).
CC5 isolates
The predominant MLST types in the CC5 isolates were ST5 and ST228 with 42 and 32 isolates, respectively. All 14 isolates from Thailand that had ceftaroline MIC values of ≥2 mg/L were ST228-MRSA-I, a lineage not typically isolated in Thailand, 25 -27 and carried the E239K variation in the nPBD either alone or in combination with E447K in the transpeptidase pocket, similar to isolates previously collected from Spain and Thailand.
8 ST228-MRSA-I[PBP2a:E239K] isolates were also isolated in Austria, Israel, Spain and Japan in this study. MRSA isolates belonging to the ST228-MRSA-I (Southern German) lineage were also isolated from Italy (n¼ 7) and Hungary (n¼ 3), with all but one carrying the N146K substitution. Plus an additional new MLST lineage that is related and has six alleles in common identified in this study.
A total of 31 MRSA strains from five Latin American countries exhibited ceftaroline MIC values of 2 mg/L and 29 belonged to the ST5-MRSA-I (UK EMRSA-3) lineage. The two exceptions were a single ST239-MRSA-III isolate from Brazil and a single isolate from Argentina that carries six of the seven MLST alleles in common with ST5, but due to a glpF allele that differs by a single SNP has a novel allelic combination, and hence MLST type, that has not been reported before. The 29 ST5-MRSA-I isolates, as well as the closely related Argentinean isolate, carried the nPBD variation M122I/E150K. The ST5-MRSA-I lineage has been previously reported as an established nosocomial clone in Argentina, Colombia and Chile, 28 -30 but it is not a predominant clone in other Latin American countries. 31 -33 Representatives of the ST5-MRSA-I[PBP2a:M122I/E150K] lineage were not found in any Characterization of ceftaroline-non-susceptible S. aureus isolates country outside Latin America, but it appears to be a welldistributed clone throughout the continent and appears to be responsible for ceftaroline MIC 90 values of 2 mg/L in many of these countries. Consistent with the geographically restricted dissemination of the M122I/E150K lineage in Latin America was the observation that this specific variation was observed in 105 PBP2a sequences in GenBank and they had all been isolated from isolates collected in a variety of Latin American countries. There were 13 ST5-MRSA-II isolates that belonged to the New York/Japan global clone that were isolated from four different Asia-Pacific countries as well as a single isolate from Italy. The majority of the PBP2a variations observed in these isolates have not been previously observed in MRSA isolates with decreased susceptibility to ceftaroline 8,34 -36 with only N146K and N236K being reported elsewhere (Table 3) . 8, 37 
CC8 isolates
The most highly represented MLST type in this CC was ST239, representing 80% (24 of 30) of the CC8 isolates. The same two nPBD variations commonly found in ST228, E239K and N146K, were found in the ST239-MRSA-III (Brazilian/Hungarian) clone and were globally disseminated. Isolates belonging to the ST239-MRSA-III[PBP2a:E239K] lineage were found in Romania (n ¼ 4), China (n ¼ 4) and Hungary (n ¼ 1). The six ST239-MRSA-III[PBP2a:N146K] isolates were collected from Turkey (n ¼ 3), Russia (n ¼ 2) and the Philippines (n ¼ 1). In addition, there were four ST239-MRSA-III[PBP2a:N146K] isolates that contained additional PBP2a variations. Single ST239-MRSA-III isolates from Brazil and South Africa contained additional N204K and G246E changes, while two isolates from Greece contained a fourth mutation, E150K, which has previously been found in isolates from Greece with decreased susceptibility to ceftaroline. 34 An additional five ST239-MRSA-III isolates, three from China and single isolates from Russia and Turkey, were identified that contained a WT PBP2a. Of the remaining six CC8 isolates, four contained a WT PBP2a protein; three ST8-MRSA-IV isolates were from Russia and a single ST247-MRSA-I isolate (Iberian clone) was from France.
Discussion
A global surveillance programme examined the potency of ceftaroline against MRSA isolates collected from 32 countries. Previous work on 2009 and 2010 MRSA surveillance isolates had identified nPBD variations in PBP2a that had been associated with slight decreases in susceptibility to ceftaroline resulting in an MIC value of 2 mg/L. 8, 34 Further, a longitudinal study on isolates collected from 1994 to 2003 from the University Hospital of Geneva also identified similar nPBD variations. 36 Prior to this work, however, limited global data regarding ceftaroline-resistant S. aureus isolates were available. This study was designed to genetically characterize contemporary MRSA isolates with a range of ceftaroline MIC values. Of the 180 MRSA isolates included in the analysis (4 ceftaroline-susceptible isolates were removed from the original set as they lacked a PBP2a protein), 56 contained a WT PBP2a protein and were distributed relatively evenly over the ceftaroline MIC range of 0.5 -2 mg/L, suggesting that PBP2a sequence-independent factors also contribute to the MIC variations observed.
The majority of PBP2a variations fell into two broad categories. The first category contained isolates possessing an E447K substitution in the transpeptidase-binding pocket of the PBD, had significantly decreased susceptibility (typically 8 mg/L on multiple testing occasions) and could be easily differentiated. All of these isolates were collected in Thailand and belonged to the same ST228-MRSA-I lineage. Significantly, the same combination of PBP2a variations has recently been reported in an ST5 MRSA isolated in the USA. 35 The second category of PBP2a variations was concentrated in the nPBD. 8, 14 The majority of these isolates contained an E150K, E239K or N146K substitution, occasionally in combination with other minor variations. Most of the isolates with these three prevalent nPBD variations generated ceftaroline MIC values of 2 mg/L. These three common nPBD variations have been identified in multiple MLST lineages and in isolates that pre-date ceftaroline usage in the clinic, 8, 34, 36 suggesting that the substitutions have occurred multiple times independently in response to selective pressure that is unrelated to ceftaroline exposure. Biochemical studies on purified PBP2a proteins with these substitutions have demonstrated that the E239K and N146K substitutions, of which the latter makes a direct contact with the second ceftaroline-binding site, do not affect the ability of ceftaroline to inhibit and acylate PBP2a and in fact resulted in a 2-fold improvement in acylation rates. 35, 38 In contrast, the protein containing the E150K change exhibited a 5-fold decrease in ceftaroline acylation. 38 Furthermore, the dissociation constants of ceftaroline binding to the allosteric site in the N146K and E150K mutants were unchanged or reduced by 2-fold, respectively. 38 These data suggest that the E150K mutant could impact the opening of the transpeptidase-binding site, but the E239K and N146K substitutions appeared to have little impact on active-site acylation. Crystal structures of the E150K and N146K mutants showed no difference in the transpeptidase-binding pocket compared with the WT protein. 38 Thus, any impact on direct binding of ceftaroline to its functional pocket would be minimal. The crystal structure of the WT protein also shows that these nPBD residues are in close proximity to the muramic acid (a fragment of peptidoglycan) found at the allosteric site and are also in the protein-protein interface of the observed dimer in the structure.
14 Thus, it is plausible that either the perturbation of a direct interaction with another protein such as PBP2 to this PBP2a nPBD region or the interaction with another natural ligand such as a peptidoglycan molecule could influence PBP2a activity at the transpeptidase active site. Significantly, the most prevalent substitutions observed in the nPBD region of PBP2a, while distributed across the surface, all convert the native negatively charged amino acid into a positively charged lysine reside, suggesting that the impacted entity is likely a positively charged molecule or region.
Although the interacting molecule(s) with this PBP2a domain is yet to be revealed, the data available to date suggest that if these residues have any impact on ceftaroline susceptibility, they do so via a ceftaroline-independent mechanism. A recent study by Fernandez et al. 39 suggested that changes in PBP2, such as C197Y and S707L, may play a role in decreased ceftaroline susceptibility. The S707L substitution was found in seven isolates examined in our study, four of which had ceftaroline MIC values of ≤1 mg/L, whereas five isolates, all of which exhibited ceftaroline MIC values of ≥2 mg/L, had a cysteine at position 197 rather than a tyrosine. Further studies will be required to elucidate the impact of these residues or identify other genetic factors that impact ceftaroline susceptibility.
The ceftaroline-susceptible breakpoints for S. aureus are currently set at ≤1 mg/L for both EUCAST and CLSI, although the breakpoints that define resistance are different (.1 mg/L for EUCAST and ≥4 mg/L for CLSI). 15, 16 The key data for the establishment of the EUCAST clinical breakpoints included the clinical response for S. aureus infections where efficacy was achieved in 100% (11/11) and 50% (2/4) of cases with ceftaroline MIC values of 1 and 2 mg/L, respectively, and did not include any molecular characterization. 40 The molecular data presented here show that the distribution of MRSA isolates that contain a WT PBP2a sequence exhibit ceftaroline MIC values that range from 0.5 to 2 mg/L and those that contain nPBD variations have MIC values that range from 0.5 to 4 mg/L. Importantly, the two distributions overlap significantly and whereas characterization of isolates exhibiting a ceftaroline MIC of 2 mg/L enriched for those carrying nPBD variations, this MRSA population cannot be effectively distinguished by MIC susceptibility testing alone. In contrast, however, the isolates that contain a substitution in the transpeptidasebinding pocket typically generated ceftaroline MIC values of 8 mg/L and were readily differentiated. This likely reflects a difference between generalized cellular changes that subtly alter the functional capacity of PBP2a in contrast to specific changes that directly impact the binding affinity of ceftaroline, a finding supported by recent biochemical studies. 35, 38 Recent pharmacokinetic/pharmacodynamic and target attainment analyses on patients with normal renal function or mild renal impairment using the intravenous 600 mg every 12 h dosing regimen of ceftaroline fosamil, as well as in an in vitro pharmacokinetic model of infection, support that the in vitro susceptibility test interpretive criteria that defines the susceptible S. aureus population could be ≤2 mg/L. 41, 42 Given the prevalence of nPBD variations that predate the release of ceftaroline fosamil, 8, 34, 36 as well as the number of MRSA isolates with a WT PBP2a that have a ceftaroline MIC of 2 mg/L, it appears that the normal MRSA population distribution is actually inhibited by ≤2 mg/L ceftaroline. In contrast, the transpeptidase-binding pocket mutations where ceftaroline binds to inhibit the function of PBP2a, result in an elevation of the ceftaroline MIC to 8 mg/L and clearly demarcate the ceftaroline-resistant isolates. These data provide an understanding of the molecular differences underpinning the distribution of ceftaroline susceptibility among MRSA. Further, they are supportive of a susceptible breakpoint for ceftaroline of ≤2 mg/L and, taken together with the pharmacokinetic/pharmacodynamic and target attainment analyses, warrant a re-examination of the breakpoints that define ceftaroline susceptibility in S. aureus.
